Cite
HARVARD Citation
Ghia, P. et al. (n.d.). Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study. Hematological oncology. pp. 86-87. [Online].